Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schwarz Group on the market entry of its environmental division PreZero in Sweden in connection with PreZero's acquisition of SUEZ’s waste management and recycling operations in Sweden.
Mandate

Vinge advises Schwarz Group on the market entry of its environmental division PreZero in Sweden in connection with PreZero's acquisition of SUEZ’s waste management and recycling operations in Sweden.

October 02, 2020 Employment and Benefits EU, Competition and Regulatory M&A Intellectual Property Environmental Law Banking and Finance Real Estate and Construction Corporate Tax Carve-Outs

SUEZ has more 50 recycling sites and around 1,000 employees in Sweden.

The transaction is subject to antitrust clearance and closing of the transaction is expected at the end of 2020.

Vinge's team consisted of Matthias Pannier, Ulrich Ziche, Linda Sengul and Jesper Lindvall together with Nina Gransäter (M&A), Mathilda Persson, Jolene Reimerson, Mika Jordan, Ellinor Wargenbrant, Christoffer Nordin, Lisa Hörnqvist, Marion Kronberg and Hayaat Ibrahim (IT & Commercial Agreements), Johan Cederblad and Olof Löfvenberg (Environmental & permits), Sara Strandberg and Veronika Garemark (Employment), Jack Bengtsson and Martin Svanberg (Financing), Sofia Bergenstråhle (IP), Kristoffer Larson (Real Estate), Maria Schultzberg (Tax), Nathalie Hughes and Carl Bruneheim (VDR assistants) as well as Jasmina Skandrani (Project assistant).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026